WO1997047289A1 - Stabilized hinokitiol and compositions containing same - Google Patents
Stabilized hinokitiol and compositions containing same Download PDFInfo
- Publication number
- WO1997047289A1 WO1997047289A1 PCT/US1997/009835 US9709835W WO9747289A1 WO 1997047289 A1 WO1997047289 A1 WO 1997047289A1 US 9709835 W US9709835 W US 9709835W WO 9747289 A1 WO9747289 A1 WO 9747289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hinokitiol
- microcapsules
- cosmetic
- preservative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
Definitions
- the present invention relates to preservatives useful m pharmaceutical and cosmetic compositions.
- the invention relates to a stabilized, anti-irritant preservative, hinokitiol.
- Hinokitiol is a wood extract obtainable from pine, cedar, etc. Methods for its production are described, for example, in JP 0586396 and JP 05105898. This material is known to have potent antimicrobial effects, and,as such, has been previously used for a variety of purposes.
- hinokitiol has been used in food preservation and prevention of discoloration (JP 78035145; JP 6277019; JP 6153788; JP 6090661; JP 5344861; JP 59085279); in combination with zinc, or with ethyl alcohol and propylene glycol for antisepsis and/or the treatment of infection(WO 9317559; JP 3133334); in detergent compositions (WO 9205240); and as a wood preservative(JP 1038203).
- Hinokitiol has also been used in various types of cosmetic and pharmaceutical compositions.
- DE 4202964 discloses a water-phase hair and body treatment comprising hinokitiol and heliotropin or a cosmetic alcohol, wherein the heliotropin and alcohol is said to synergistically enhance the antimicrobial activity of hinokitiol.
- JP 2243607 describes the use in cosinetic compositions of a preservative containing hinokitiol in combination with phenoxyethanol and phthalate ester.
- hinokitiol also possesses a heretofore unappreciated anti-irritancy effect.
- hinokitiol has been shown to be an effective preservative under a wide variety of conditions, it is not itself completely stable under all conditions in which its use might be desired. For example, its use in compositions in polyethylene plastic containers can result in a discolored and/or unpleasant-smelling product. It also may not be stable after direct contact with light or air. These are limitations which under ordinary circumstances would not be acceptable, and which would recommend against its use in a cosmetic composition, where appearance and fragrance can be critical.
- hinokitiol can itself be stabilized in the desired composition, and yet retain its useful biological properties, such as antimicrobial and anti-irritant activity.
- the present invention provides the means by which hinokitiol can be effectively used in cosmetic compositions.
- the present invention provides cosmetic and pharmaceutical compositions containing hinokitiol-containing microcapsules, the microcapsules comprising a matrix containing collagen and a glycosaminoglycan.
- the microcapsule provides adequate stability to the hinokitiol, preventing it from discoloration and unpleasant odor in the composition containing same, while nonetheless permitting the hinokitiol to exert its preservative and anti-irritant effect on the composition containing it.
- the invention also provides a method for preserving a cosmetic or pharmaceutical composition, comprising adding to the composition a preservative-effective amount of the hinokitiol containing microcapsules, as well as a method for reducing irritation on the skin by application of a cosmetic composition containing an effective amount of hmokitiol-contaming microspheres.
- microcapsules used m the present invention are prepared according to the methodology disclosed in US Patent No. 5,395,620, the contents of which are incorporated herein by reference. Briefly, the microcapsules are prepared by combining a solution containing atelocollagen and a solution containing a polyholoside, preferably a glycosaminoglycan, m the presence of the hinokitiol and a crosslmkmg agent.
- Atelocollagen is a type of collagen from which the telopeptides which crosslink typical collagen have been removed.
- glycosammoglyeans are well known in the art, and for the present purposes may be selected, for example, from chondroitm 4-sulfate, chondroitm 6-sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, heparm and derivatives thereof; preferably the cosmetically or pharmaceutically acceptable salts, such as calcium or sodium salts, are employed.
- the amount of glycosaminoglycan present in the microcapsules will typically be about 15-50% by weight of the atelocollagen used in the formulation.
- the amount of atelocollagen m the starting solution is approximately 0.5-2% by weight, and the glycosaminoglycan solution contains about 0.5-4%, preferably 0.5-2% by weight of glycosammoglycans.
- both the atelocollagen and the glycosammoglycans are of marine origin.
- Cross-linking reagents useful in preparing the microcapsules include, but are not limited to, an acid dichloride, an acid anhydride, or a dibasic or polybasic carboxylic acid. With respect to the hinokitiol, this material is present in an amount of between 0.01-10% by weight, preferably 0.5-4% by weight, of the starting solution.
- the microcapsules containing hinokitiol provide an unexpectedly high level of preservative efficacy, while itself remaining stable in the compositions m which it is included.
- the retention of antimicrobial activity, at the levels seen herein, is particularly surprising m view of the fact that the hinokitiol itself is not expected to be m direct contact with the medium is intended to preserve.
- the microcapsules m which the hinokitiol is contained are essentially impermeable, i.e., there is apparently substantially no leakage of the hinokitiol into the medium in which the microcapsules are contained, as evidenced by the absence of unpleasant odor or color m the products containing them. Since the hinokitiol is used in quantities essentially the same as used m its unencapsulated form, the substantially complete retention of antimicrobial activity by the "protected" hinokitiol is quite unexpected.
- the encapsulated hinokitiol can be used in a wide variety of cosmetic and/or pharmaceutical compositions, as well as a preservative in food compositions.
- the hinokitiol can be used in virtually any form in which such compositions may be formulated, e.g., solutions, colloidal dispersions, emulsions, suspensions, creams, lotions, gels, foams, mousses and the like.
- Methods and components for preparing such compositions are well known in the art, and can be found for example, in CTFA International Cosmetics Ingredients Dictionary, The Cosmetic, Toiletry, and Fragrance Association, Washington, DC, 1991.
- the amount of the hmokitiol-containmg microspheres will vary depending on the nature of the composition and the amount of hinokitiol contained in the microspheres, but a preservative-effective amount of hinokitiol per se will generally be in the range of from about 0.1-1% by weight of the composition as a whole, given the amount of hinokitiol in the microspheres is as stated above. It is well within the skill of the art to determine the desired microsphere concentration in the formulation, given these parameters.
- compositions of the present invention will also comprise a pharmaceutically or cosmetically acceptable carrier, in an amount appropriate to accomodate the other components of the formulation.
- pharmaceutically or cosmetically acceptable carrier refers to a vehicle, for either pharmaceutical or cosmetic use, which vehicle delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms.
- pharmaceutical or “cosmetic” will be understood to encompass both human and animal pharmaceuticals or cosmetics.
- the carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions, suspensions, creams, lotions, gels, foams, mousses and the like.
- the carrier is a suspension, dispersion or emulsion.
- the emulsion may be an oil-in-water emulsion, or a water-in-oil emulsion. These emulsions contain one or more oil components, an aqueous component, and a specific emulsifier component chosen depending on the nature of the desired emulsion.
- the oil component may be any pharmaceutically or cosmetically acceptable material which is substantially insoluble in water. These materials can be found for example in the CTFA International Dictionary of Cosmetic Ingredients as well as the U.S. Pharmacopoeia or equivalent sources.
- Suitable oil components include, but are not limited to, natural oils, such as coconut oil; hydrocarbons, such as mineral oil and hydrogenated polyisobutene; fatty alcohols, such as octyldodecanol; esters, such as C12-15 alkyl benzoate; diesters, such as propylene glycol dipelargonate; triesters, such as glyceryl trioctanoate; sterol derivatives, such as lanolin; animal waxes, such as beeswax; plant waxes, such as carnauba; mineral waxes, such as ozokerite; petroleum waxes, such as paraffin wax; synthetic waxes, such as polyethylene; and mixtures thereof.
- Suitable oil components may also be silicones including, but not limited to, volatile silicones such as cyclomethicone; polymeric silicones such as dimethicone; alkylated derivatives of polymeric silicones, such as cetyl dimethicone and lauryl trimethicone; hydroxylated derivatives of polymeric silicones, such as dir ⁇ ethiconol; and mixtures thereof.
- volatile silicones such as cyclomethicone
- polymeric silicones such as dimethicone
- alkylated derivatives of polymeric silicones such as cetyl dimethicone and lauryl trimethicone
- hydroxylated derivatives of polymeric silicones such as dir ⁇ ethiconol
- mixtures thereof such as dir ⁇ ethiconol
- the aqueous component refers to any pharmaceutically or cosmetically acceptable material consisting essentially or predominantly of water.
- the oil-in- water emulsifier will be an emulsifier having a hydrophilic- lipoph ' ilic balance (HLB) of at least 6, or a mixture of such emulsifiers with one or more water-in-oil emulsifiers (i.e. , emulsifiers having an HLB of from about 2 to about 6) , in which case the type and amount of each emulsifier present in the mixture is selected such that the effective HLB of the resultant oil-in-water emulsifier component is at least about 6.
- HLB hydrophilic- lipoph ' ilic balance
- Suitable oil-in-water emulsifiers include, but are not limited to, sorbitol derivatives, such as sorbitan monolaurate and polysorbate 20; ethoxylated alcohols such as laureth-23, ethoxylated fatty acids such as PEG-1000 stearate; amidoamine derivatives such as stearamidoethyl diethylamine; sulfate esters such as sodium lauryl sulfate; phosphate esters such as DEA cetyl phosphate; fatty acid amine salts such as TEA stearate; and mixtures thereof.
- sorbitol derivatives such as sorbitan monolaurate and polysorbate 20
- ethoxylated alcohols such as laureth-23, ethoxylated fatty acids such as PEG-1000 stearate
- amidoamine derivatives such as stearamidoethyl diethylamine
- sulfate esters such
- the emulsion may also be a water-in-oil emulsion.
- a water-in-oil emulsifier is employed. This refers to any cosmetically acceptable emulsifier having an HLB of no greater than 6, preferably from about 2 to about 4.
- Suitable water-in-oil emulsifiers include, but are not limited to, sorbitan derivatives such as sorbitan laurate and sorbitan palmitate; alkoxylated alcohols such as laureth-4; hydroxylated derivatives of polymeric silicones, such as dimethicone copolyol; alkylated derivatives of hydroxylated polymeric silicones, such as cetyl dimethicone copolyol; glyceryl esters such as polyglyceryl-4 isostearate; beeswax derivatives such as sodium isostearoyl-2 lactylate; lecithin; and mixtures thereof.
- sorbitan derivatives such as sorbitan laurate and sorbitan palmitate
- alkoxylated alcohols such as laureth-4
- hydroxylated derivatives of polymeric silicones such as dimethicone copolyol
- alkylated derivatives of hydroxylated polymeric silicones such as cety
- the active component of the pharmaceutical or cosmetic compositions will depend on the intended purpose of the compositions.
- active agents which may form part of the composition include, but are not limited to, those that improve or eradicate age spots, keratoses and wrinkles, analgesics, anesthetics, anti-acne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antipruritic agents, antiemetics, antimotion sickness agents, anti- inflammatory agents, antihyperkeratolytic agents, anti-dry skin agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging agents, antiwrinkle agents, antiasthmatic agents and bronchodilators, sunscreen agents, antihistamine agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, topical cardiovascular agents, clotrimazole, ketocon
- the composition is a sunscreen-containing composition.
- sunscreen refers to any material which is capable of protecting human skin from ultraviolet radiation having a wavelength of from about 280 to about 400nm, by effectively absorbing such radiation, and/or reflecting or scattering such radiation away from the surface of human skin.
- Suitable sunscreens for purposes of this invention include but not limited to, titanium derivatives such as titanium dioxide, especially titanium dioxide having an average particle size of from 10 to 100 nanometers, most especially titanium dioxide having an average particle size of from 10 to 100 nanometers and comprising a hydrophobic coating agent to minimize agglomeration; zinc derivatives such as zinc oxide, especially zinc oxide having an average particle size of from 10 to 100 nanometers; melanin and melanin derivatives; dioxybenzone; 2-ethylhexyl 2-cyano-3,3- diphenylacrylate; 2-ethylhexyl p-methoxycinnamate; 2-ethylhexyl salicyLate; homosalate; menthyl anthranilate; oxybenzone; octyl dimethyl PABA; red petrolatum; ferulic acid ester; and mixtures thereof .
- titanium derivatives such as titanium dioxide, especially titanium dioxide having an average particle size of from 10 to 100 nanometers, most especially titanium dioxide having
- compositions may also comprise additional preservatives, fragrances, emollients, antiseptics, antunflammatories, antibacterials, stabilizers, antioxidants, vitamins, pigments, dyes, humectants, and propellants, as well as other classes of materials the presence of which in the compositions may be cosmetically, medicinally, or otherwise desired.
- additional preservatives fragrances, emollients, antiseptics, antunflammatories, antibacterials, stabilizers, antioxidants, vitamins, pigments, dyes, humectants, and propellants, as well as other classes of materials the presence of which in the compositions may be cosmetically, medicinally, or otherwise desired.
- Thalaspheres® (30 ⁇ m) containing hinokitiol are provided by Bioetica, Inc., Portland, Maine) .
- the composition of the Thalaspheres®, in grams per lOOg, is as follows:
- Xanthan gum 0.5 0.71% atelocollagen 0.441 1, .47% chondroitm 0.165 0. .55%
- the encapsulated hinokitiol as described in Example 1, is incorporated by art-recognized procedures into a sunscreen- containing dispersion, a moisturizing cream emulsion, and a skin desensitizing lotion emulsion.
- the components are as follows :
- the formulations so prepared exhibit no deterioration, no discoloration and no unpleasant odor even after prolonged storage, showing the encapsulated hinokitiol retains its preservative effect while at the same time being stabilized by the encapsulation.
- Hinokitiol alone is tested for its ability to prevent irritation.
- Hinokitiol (unencapsulated, 0.5% by weight) is applied to the ventral forearms of panelists. The material is allowed to absorb for twenty minutes and then Balsam of Peru, an irritant, is applied to the test sites. Skin irritation is measured in terms of increase in skin redness. Cola n ⁇ t ⁇ da(10% hydro-alcohol 1:1) is used as a positive control.
- the degree of redness is measured with the Minolta chromameter and compared with the positive and negative controls.
- the positive control is the color of skin treated with Balsam of Peru alone and the negative control is the skin treated with cola material challenged as with the hinokitiol.
- Hinokitiol exhibits a 71% activity, as compared with an average of 67% for cola.
- the encapsulated hinokitiol is then tested for its retained anti-irritant activity.
- Encapsulated hinokitiol, prepared as described above, is prepared in 4.2% and 2.8% aqueous solution. These solutions are tested against empty microcapsules, as well as against cola n ⁇ t ⁇ da(10% hydro-alcohol 1:1), using the same protocol as described in the previous example.
- results show that the activity of the encapsulated hinokitiol at 4.2% is approximately equivalent to that of 10% cola (61% vs 64%, respectively) m reducing the onset of irritation due to Balsam of Peru.
- the lower concentration of hinokitiol capsules shows 53% activity, while empty microcapsules show 28% activity.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97929825A EP0952852A1 (en) | 1996-06-12 | 1997-06-09 | Stabilized hinokitiol and compositions containing same |
JP10501709A JP2000512294A (en) | 1996-06-12 | 1997-06-09 | Stabilized hinokitiol and composition containing the same |
AU33794/97A AU3379497A (en) | 1996-06-12 | 1997-06-09 | Stabilized hinokitiol and compositions containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/662,870 | 1996-06-12 | ||
US08/662,870 US5811114A (en) | 1996-06-12 | 1996-06-12 | Stabilized hinokitiol and compositions containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997047289A1 true WO1997047289A1 (en) | 1997-12-18 |
Family
ID=24659581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/009835 WO1997047289A1 (en) | 1996-06-12 | 1997-06-09 | Stabilized hinokitiol and compositions containing same |
Country Status (7)
Country | Link |
---|---|
US (1) | US5811114A (en) |
EP (1) | EP0952852A1 (en) |
JP (1) | JP2000512294A (en) |
AU (1) | AU3379497A (en) |
CA (1) | CA2257850A1 (en) |
WO (1) | WO1997047289A1 (en) |
ZA (1) | ZA975204B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1214926A1 (en) * | 2000-12-12 | 2002-06-19 | Kabushiki Kaisha Kishohin Kagaku Kaiho Kenkyujo | Topical composition |
EP1441685A2 (en) * | 2001-10-05 | 2004-08-04 | Color Access, Inc. | Anti-irritating rosacea treatment |
EP0989846B1 (en) * | 1997-09-30 | 2004-11-24 | E-L Management Corp. | Non-irritating cosmetic and pharmaceutical compositions |
WO2005018322A1 (en) * | 2003-08-22 | 2005-03-03 | Danisco A/S | Encapsulated antimicrobial material |
US8337923B2 (en) | 2003-08-22 | 2012-12-25 | Dupont Nutrition Biosciences Aps | Encapsulated antimicrobial material |
WO2017021014A1 (en) * | 2015-08-06 | 2017-02-09 | Laboratori Derivati Organici Spa | Compositions comprising dermatan sulfate and chondroitin sulfate and use thereof in cosmetological compositions |
FR3064179A1 (en) * | 2017-03-24 | 2018-09-28 | Greenpharma | CONSERVATIVE AGENT CONTAINING HINOKITIOL WITH AT LEAST ONE ACID AND COMPOSITIONS PRESERVED THEREBY |
US10271557B2 (en) | 2003-08-22 | 2019-04-30 | Dupont Nutrition Biosciences Aps | Composition comprising a bacteriocin and an extract from a plant of the Labiatae family |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685965B1 (en) * | 1997-10-22 | 2004-02-03 | Industria E Comercio De Cosmeticos Natura Ltda. | Process for stabilizing levogyre ascorbic acid (laa), a stable aqueous laa composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment |
JP4087938B2 (en) * | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | Antibacterial agent comprising branched cyclodextrin inclusion compound of hinokitiols and composition containing the same |
JP3134068B2 (en) * | 1999-02-03 | 2001-02-13 | 株式会社トピックス | Method for producing hinokitiol-containing aromatic antibacterial agent |
US6217913B1 (en) * | 1999-07-15 | 2001-04-17 | Fatemeh Mohammadi | Cosmetic compositions with gorgonian extract |
US20040120915A1 (en) * | 2002-12-19 | 2004-06-24 | Kaiyuan Yang | Multifunctional compositions for surface applications |
US7211249B2 (en) * | 2003-03-17 | 2007-05-01 | Color Access, Inc. | Heat-generating composition for topical application to skin |
US20070027152A1 (en) * | 2005-07-27 | 2007-02-01 | Clark Kathleen L | Topical anti-pruritic compositions and methods of action of same |
JP2010534675A (en) * | 2007-07-24 | 2010-11-11 | マローネ バイオ イノベーションズ,インコーポレイテッド | Hinokitiol as a plant herbicide |
US9717818B2 (en) * | 2009-05-08 | 2017-08-01 | Medline Industries, Inc. | Absorbent articles having antimicrobial properties and methods of manufacturing the same |
US9180112B2 (en) * | 2010-03-23 | 2015-11-10 | Ermis Labs, LLC | Dermal compositions containing gorgonian extract |
JP5642002B2 (en) * | 2011-03-28 | 2014-12-17 | 株式会社コーセー | Vesicle-containing composition, cosmetic or external preparation containing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5268174A (en) * | 1988-09-29 | 1993-12-07 | Kabushiki Kaisha Sangi | Antimicrobial hydroxyapatite powders containing hinokitiol, protamine or sorbic acid |
US5395620A (en) * | 1989-01-31 | 1995-03-07 | Coletica | Biodegradable microcapsules having walls composed of crosslinked atelocollagen and polyholoside |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5335145B2 (en) * | 1973-02-09 | 1978-09-26 | ||
JPS5985279A (en) * | 1982-11-08 | 1984-05-17 | Seiwa Kasei Kk | Preventing animal or plant from blackening or browning |
JPS6438203A (en) * | 1987-08-05 | 1989-02-08 | Aomori Prefecture | Natural wood protective colorant |
JP2795879B2 (en) * | 1989-03-16 | 1998-09-10 | 株式会社アルソア央粧 | Preservatives for cosmetics |
JPH03133334A (en) * | 1989-10-19 | 1991-06-06 | Takara Nenryo Kogyo Kk | Antiseptic composition and antiseptic water containing the same |
ATE175433T1 (en) * | 1990-08-17 | 1999-01-15 | Yoshihide Hagiwara | ACTIVE ANTIOXIDANT SUBSTANCE AND USE THEREOF |
WO1992005240A1 (en) * | 1990-09-14 | 1992-04-02 | Otsuka Pharmaceutical Co., Ltd. | Detergent composition |
JP2777680B2 (en) * | 1991-08-22 | 1998-07-23 | 富田製薬株式会社 | Salty seasoning having antimicrobial and insect repellent effects and method for producing the same |
JPH05105898A (en) * | 1991-09-25 | 1993-04-27 | Sumitomo Seika Chem Co Ltd | Method for separating acid oil from essential plant oil |
JPH0586396A (en) * | 1991-09-25 | 1993-04-06 | Jiyumoku Chiyuushiyutsu Seibun Riyou Gijutsu Kenkyu Kumiai | Refining of hinokitiol |
DE4202964A1 (en) * | 1992-02-01 | 1993-08-05 | Wella Ag | HAIR AND BODY TREATMENT |
EP0589047B1 (en) * | 1992-03-13 | 1999-06-09 | Otsuka Pharmaceutical Co., Ltd. | Method of treating infectious disease, method of preventing putrefaction of cosmetic, and antibacterial/antifungal agent and cosmetic |
JPH0690661A (en) * | 1992-09-09 | 1994-04-05 | Sumitomo Seika Chem Co Ltd | Freshness-keeping material containing hinokitiol |
JP2640899B2 (en) * | 1992-11-20 | 1997-08-13 | 耕平 森 | Preservative method of moromi pickles and moromi pickles |
JP3424930B2 (en) * | 1992-12-09 | 2003-07-07 | 協和醗酵工業株式会社 | N-acylglutamine derivatives |
JPH06277019A (en) * | 1993-03-31 | 1994-10-04 | Gunze Ltd | Preservative containing red koji and production of food and feed utilizing the same |
-
1996
- 1996-06-12 US US08/662,870 patent/US5811114A/en not_active Expired - Fee Related
-
1997
- 1997-06-09 EP EP97929825A patent/EP0952852A1/en not_active Withdrawn
- 1997-06-09 CA CA002257850A patent/CA2257850A1/en not_active Abandoned
- 1997-06-09 WO PCT/US1997/009835 patent/WO1997047289A1/en not_active Application Discontinuation
- 1997-06-09 JP JP10501709A patent/JP2000512294A/en active Pending
- 1997-06-09 AU AU33794/97A patent/AU3379497A/en not_active Abandoned
- 1997-06-12 ZA ZA9705204A patent/ZA975204B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5268174A (en) * | 1988-09-29 | 1993-12-07 | Kabushiki Kaisha Sangi | Antimicrobial hydroxyapatite powders containing hinokitiol, protamine or sorbic acid |
US5395620A (en) * | 1989-01-31 | 1995-03-07 | Coletica | Biodegradable microcapsules having walls composed of crosslinked atelocollagen and polyholoside |
Non-Patent Citations (1)
Title |
---|
See also references of EP0952852A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0989846B1 (en) * | 1997-09-30 | 2004-11-24 | E-L Management Corp. | Non-irritating cosmetic and pharmaceutical compositions |
EP1214926A1 (en) * | 2000-12-12 | 2002-06-19 | Kabushiki Kaisha Kishohin Kagaku Kaiho Kenkyujo | Topical composition |
EP1441685A2 (en) * | 2001-10-05 | 2004-08-04 | Color Access, Inc. | Anti-irritating rosacea treatment |
EP1441685A4 (en) * | 2001-10-05 | 2007-10-31 | Color Access Inc | Anti-irritating rosacea treatment |
WO2005018322A1 (en) * | 2003-08-22 | 2005-03-03 | Danisco A/S | Encapsulated antimicrobial material |
US8337923B2 (en) | 2003-08-22 | 2012-12-25 | Dupont Nutrition Biosciences Aps | Encapsulated antimicrobial material |
US10271557B2 (en) | 2003-08-22 | 2019-04-30 | Dupont Nutrition Biosciences Aps | Composition comprising a bacteriocin and an extract from a plant of the Labiatae family |
WO2017021014A1 (en) * | 2015-08-06 | 2017-02-09 | Laboratori Derivati Organici Spa | Compositions comprising dermatan sulfate and chondroitin sulfate and use thereof in cosmetological compositions |
AU2016304201B2 (en) * | 2015-08-06 | 2022-03-31 | Laboratori Derivati Organici Spa | Compositions comprising dermatan sulfate and chondroitin sulfate and use thereof in cosmetological compositions |
FR3064179A1 (en) * | 2017-03-24 | 2018-09-28 | Greenpharma | CONSERVATIVE AGENT CONTAINING HINOKITIOL WITH AT LEAST ONE ACID AND COMPOSITIONS PRESERVED THEREBY |
Also Published As
Publication number | Publication date |
---|---|
CA2257850A1 (en) | 1997-12-18 |
EP0952852A4 (en) | 1999-11-03 |
US5811114A (en) | 1998-09-22 |
EP0952852A1 (en) | 1999-11-03 |
AU3379497A (en) | 1998-01-07 |
ZA975204B (en) | 1997-12-31 |
JP2000512294A (en) | 2000-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5811114A (en) | Stabilized hinokitiol and compositions containing same | |
EP0686023B1 (en) | Sunscreens containing oat extracts | |
AU671940B2 (en) | Use of deformable hollow particles in a cosmetic and/or dermatological composition containing fatty substances | |
US4970216A (en) | Skin treatment composition and method | |
US5560917A (en) | Cosmetic makeup composition | |
US6146618A (en) | Disappearing color sunscreen compositions | |
US6238650B1 (en) | Sunscreen composition containing sol-gel microcapsules | |
US4847267A (en) | Skin treatment composition and method | |
AU681805B2 (en) | Product for topical application containing a lipase and an active ingredient precursor | |
CA2282699C (en) | Combination of erythrulose and a reducing sugar with self-browning properties | |
US20050031655A1 (en) | Emulsion composition | |
JP2002212022A (en) | O/w type emulsified gel cream including one or more kinds of acryloyl dimethyl taurine ammonium/vinyl pyrrolidone copolymer | |
JP2002501014A (en) | Cosmetic or dermatological preparations with low lipid flow | |
WO1996014051A1 (en) | Sprayable compositions containing dispersed powders and methods for using the same | |
JP2000503677A (en) | Stable light protection composition | |
JP2004026826A (en) | Cosmetic and/or dermatologic use of composition containing at least one oxidation-sensitive hydrophilic component stabilized by at least one maleic anhydride copolymer | |
JP2001518070A (en) | Cosmetic or pharmaceutical preparation with reduced sticky feel | |
US7144570B2 (en) | Sunscreen compositions and methods of use thereof | |
US6114377A (en) | Antimicrobial cosmetic compositions | |
US6858200B2 (en) | Sunscreen formulations | |
JP2000143438A (en) | Water-in-oil emulsion type mixture containing high water content and one kind or more alkylmethicone copolyol and/or alkyldimethicone copolyol and cationic polymer | |
JP2002212025A (en) | O/w emulsion containing one or more kinds of ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymers | |
US5620680A (en) | Cosmetic and dermatological light protection formulations having an active content of cis-urocaninic acid | |
JP2000026233A (en) | Preparation of w/o type emulsion containing increased water content by containing additionally one or more kinds of alkylmethicone copolyol and/or alkyldimethicone copolyol | |
US7135165B2 (en) | Multiphase sunscreen compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2257850 Country of ref document: CA Ref country code: CA Ref document number: 2257850 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997929825 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997929825 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997929825 Country of ref document: EP |